Legacy Wealth Asset Management LLC Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Legacy Wealth Asset Management LLC increased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 31.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 185,472 shares of the company's stock after purchasing an additional 44,635 shares during the quarter. Takeda Pharmaceutical makes up about 0.8% of Legacy Wealth Asset Management LLC's portfolio, making the stock its 17th biggest position. Legacy Wealth Asset Management LLC's holdings in Takeda Pharmaceutical were worth $2,758,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Blair William & Co. IL boosted its position in Takeda Pharmaceutical by 8.1% during the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after acquiring an additional 913 shares in the last quarter. Vise Technologies Inc. boosted its position in Takeda Pharmaceutical by 3.1% during the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock valued at $459,000 after acquiring an additional 1,026 shares in the last quarter. Sage Rhino Capital LLC boosted its position in Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after acquiring an additional 1,538 shares in the last quarter. Vident Advisory LLC boosted its position in Takeda Pharmaceutical by 13.5% during the 4th quarter. Vident Advisory LLC now owns 13,606 shares of the company's stock valued at $180,000 after acquiring an additional 1,616 shares in the last quarter. Finally, OLD Mission Capital LLC boosted its position in Takeda Pharmaceutical by 13.7% during the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after acquiring an additional 1,687 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Down 0.5%

Shares of TAK traded down $0.07 during midday trading on Thursday, hitting $14.96. 431,787 shares of the company's stock traded hands, compared to its average volume of 1,929,329. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43. The firm's fifty day moving average is $14.65 and its 200-day moving average is $14.08. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $47.60 billion, a price-to-earnings ratio of 37.40, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. As a group, sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.